US2021132023A1PendingUtilityA1

Methods of identifying potential components for targeted drug delivery compositions

Assignee: WARSAW ORTHOPEDIC INCPriority: Mar 26, 2009Filed: Jan 4, 2021Published: May 6, 2021
Est. expiryMar 26, 2029(~2.7 yrs left)· nominal 20-yr term from priority
A61K 33/06A61P 35/00G01N 33/15A61P 27/02A61K 47/60
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods of preparing compositions for preferential distribution of active agents to injury sites are provided. The compositions may comprise a polymer with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature. Methods of identifying suitable components for such compositions are also disclosed.

Claims

exact text as granted — not AI-modified
1 . A method of preparing compositions for preferential distribution of active agents, the method comprises:
 preparing a solution comprising a delivery ligand comprising polyethylene glycol and one or more active agents comprising a magnesium salt;   subjecting the solution to one or more conditions to induce separation of phases in the solution; and   isolating a phase comprising delivery ligand-active agent complexes.   
     
     
         2 . The method of  claim 1 , wherein the isolated phase has a concentration of delivery ligand-active agent complexes above a threshold concentration. 
     
     
         3 . The method of  claim 1 , wherein the delivery ligand and the at least one active agent are selected so the interaction between them is mainly of an ionic nature. 
     
     
         4 . The method of  claim 1 , wherein the solution comprises between about 10% and about 60% weight per volume of the delivery ligand. 
     
     
         5 . The method of  claim 1 , wherein the polyethylene glycol has a molecular weight of about 200 Da to about 24,000 Da. 
     
     
         6 . The method of  claim 1 , wherein the magnesium salt is magnesium chloride. 
     
     
         7 . The method of  claim 1 , wherein the concentration of the active agent in the solution is about 0.8%. 
     
     
         8 . The method of  claim 1 , wherein the magnesium salt is magnesium sulfate. 
     
     
         9 . The method of  claim 1 , wherein the solution comprises between about 30 and about 40% of the delivery ligand. 
     
     
         10 . A method of identifying potential components for compositions for preferential distribution of active agents, the method comprises:
 preparing a solution comprising a delivery ligand comprising polyethylene glycol and one or more active agents comprising a magnesium salt;   subjecting the solution to one or more conditions to induce separation of phases in the solution; and   determining whether one or more phases comprise delivery ligand-active agent complexes.   
     
     
         11 . The method of  claim 10 , wherein one or more phases have a concentration of delivery ligand-active agent complexes above a threshold concentration. 
     
     
         12 . The method of  claim 10 , wherein the delivery ligand and the at least one active agent are selected so the interaction between them is mainly of an ionic nature. 
     
     
         13 . The method of  claim 10 , wherein the solution comprises between about 10% and about 60% weight per volume of the delivery ligand. 
     
     
         14 . The method of  claim 10 , wherein the polyethylene glycol has a molecular weight of about 200 Da to about 24,000 Da. 
     
     
         15 . The method of  claim 10 , wherein the magnesium salt is magnesium chloride. 
     
     
         16 . The method of  claim 10 , wherein the concentration of the active agent in the solution is about 0.8%. 
     
     
         17 . The method of  claim 10 , wherein the magnesium salt is magnesium sulfate. 
     
     
         18 . The method of  claim 10 , wherein the solution comprises between about 30 and about 40% of the delivery ligand.

Join the waitlist — get patent alerts

Track US2021132023A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.